A recent publication describes a model-based population PK and exposure-response analysis for Astegolimab in Patients with severe asthma. This analysis supports the rationale for Astegolimab dosing as the highest dose tested in the phase 2 study was predicted to result in close to the maximum effect, and no substantial additional response should be expected with higher doses.
Read the publication here
